항체 생산 시장 : 제품, 항체, 공급원, 공정별 - 예측(-2031년)

Antibody Production Market by Product [Bioreactors (Single-use, Reusable), Chromatography, Filtration, Cell Lines, Media, Buffers, Resins], Antibody [Monoclonal, Polyclonal], Source [Mice, Rabbit], Process [Downstream, Upstream] - Global Forecast to 2031

The antibody production market is projected to reach $58.35 billion by 2031, at a CAGR of 11.4% from 2024 to 2031. After secondary and primary research and an in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, opportunities, challenges, and trends.

The growth of the antibody production market is driven by the growing demand for targeted antibodies, increasing investments in R&D by pharma & biotech companies, the growing prevalence of cancer and autoimmune diseases, the increasing use of immunoassays, and advancements in bioprocessing technologies. However, the high costs of antibody production and stringent regulatory frameworks restrain the growth of this market.

Furthermore, the growing applications of antibodies in clinical trials and medical research, significant potential in developing countries, and the growing risk and prevalence of infectious diseases are expected to generate growth opportunities for the players operating in this market. However, the complex nature of monoclonal antibodies is a challenge for market stakeholders.

Based on product, the antibody production market is segmented into instruments, consumables, and software. In 2024, the instruments segment is expected to account for the largest share of the antibody production market. The need for high-volume and scalable production of antibodies for commercial use, the need for separation, purification, and isolation of antibodies, and the growing need for mass production of antibodies for therapeutic applications are major factors contributing to the segment's large share.

Based on antibody type, the antibody production market is segmented into monoclonal antibodies, polyclonal antibodies, antibody segments, and recombinant antibodies. The monoclonal antibodies segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the growing applications of monoclonal antibodies in the treatment of diseases and disorders, the growing use of monoclonal antibodies for cancer treatment, and the increasing focus of pharmaceutical & biotechnology companies on the development of monoclonal antibody-based therapeutics.

Based on source, the antibody production market is segmented into mice, rabbits, and other sources. In 2024, the mice segment is expected to account for the largest share of the antibody production market. Due to the availability, low cost, and quick production time for mouse mAbs, humanization of mouse mAbs has been implemented on a large scale. Furthermore, mouse husbandry is easier than rabbit husbandry, and the genetic approaches to engineering antibodies through recombinant technologies are more established for mice than for other animals, such as rabbits, making mice a preferred choice for antibody production.

Based on process, the antibody production market is segmented into upstream and downstream. In 2024, the downstream segment is expected to account for the larger share of the antibody production market. The segment's large share can be attributed to the high preference for downstream processing as it is used for the recovery and purification of biosynthetic products, including antibodies from natural sources such as animal or plant tissue or fermentation broth, including the recycling of salvageable components and the proper treatment and disposal of waste.

Based on end user, the antibody production market is segmented into pharmaceutical & biotechnology companies, clinical research organizations & contract development & manufacturing organizations, and other end users. The pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment is driven by the expansion of antibody manufacturing facilitates, increasing R&D investments by pharma & biotech companies, the growing prevalence of chronic & infectious diseases, and the need to develop antibody-based therapeutics for these diseases. In addition, initiatives by pharma and biotech companies to launch antibody-based therapeutics are further expected to drive the segment's growth.

An in-depth analysis of the geographical scenario in the antibody production market provides detailed qualitative and quantitative insights about five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the antibody production market, followed by Europe and Asia-Pacific. Technological advancements in bioprocessing, the high number of industry-academia collaborations for research & development of antibodies, the high prevalence of chronic diseases, and the high demand for biologics are expected to support North America's largest share.

The key companies operating in the antibody production market include Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KgaA (Germany), Eppendorf SE (Germany), Sartorius AG (Germany), Danaher Corporation (U.S.), Waters Corporation (U.S.), Shimadzu Corporation (Japan), Solaris Biotechnology Srl (Italy), and Infors AG (Switzerland).

Scope of the Report:

Antibody Production Market Assessment-by Product

• Instruments
  • Bioreactors
• Single-use Bioreactors
• Reusable Bioreactors
  • Chromatography Systems
  • Filtration Systems
  • Other Instruments

(Note: Other instruments include shakers, mixers, incubators, sterilizers, centrifuges, and bioprocessing containers.)

• Consumables
  • Cell Lines & Media
  • Buffers & Reagents
  • Chromatography Columns & Resins
  • Other Consumables

(Note: Other consumables include membrane adsorbers, cell disruption reagents, pipettes, syringes, vials, closures, tubing, connectors, and sensors.)

• Software

Antibody Production Market Assessment-by Antibody Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Antibodies

Antibody Production Market Assessment-by Source

• Mice
• Rabbits
• Other Sources

(Note: Other sources include goats, sheep, and chicken.)

Antibody Production Market Assessment-by Process

• Downstream
• Upstream

Antibody Production Market Assessment-by End User

• Pharmaceutical & Biotechnology Companies
• Clinical Research Organizations & Contract Development & Manufacturing Organizations
• Academic & Research Institutes

Antibody Production Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Rest of APAC (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa

TABLE OF CONTENTS

1. Overview

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Market Dynamics
    • 4.2.1.1. Drivers
      • 4.2.1.1.1. Growing Demand for Targeted Antibodies
      • 4.2.1.1.2. Increasing Investments In R&D By Pharma & Biotech Companies
      • 4.2.1.1.3. High Burden and Growing Prevalence of Cancer and Autoimmune Diseases
      • 4.2.1.1.4. Increasing Use of Immunoassays
      • 4.2.1.1.5. Advancements In Bioprocessing Technologies
    • 4.2.1.2. Restraints
      • 4.2.1.2.1. High Cost of Antibody Production
      • 4.2.1.2.2. Stringent Regulatory Frameworks
    • 4.2.1.3. Opportunities
      • 4.2.1.3.1. Growing Applications of Antibodies in Clinical Trials and Medical Research
      • 4.2.1.3.2. Significant Opportunities from Developing Countries.
      • 4.2.1.3.3. Growing Risk and Prevalence of Infectious Diseases
    • 4.2.1.4. Challenges
      • 4.2.1.4.1. Complex Nature of Monoclonal Antibodies
• 4.3. Regulatory Analysis
• 4.4. Porter's Five Forces Analysis
• 4.5. Pricing Analysis

5. Antibody Production Market Assessment-by Product

• 5.1. Overview
• 5.2. Instruments
  • 5.2.1. Bioreactors
    • 5.2.1.1. Reusable Bioreactors
    • 5.2.1.2. Single-use Bioreactors
  • 5.2.2. Chromatography Systems
  • 5.2.3. Filtration Systems
  • 5.2.4. Other Instruments
• 5.3. Consumables
  • 5.3.1. Cell Lines & Media
  • 5.3.2. Buffers & Reagents
  • 5.3.3. Chromatography Columns & Resins
  • 5.3.4. Other Consumables
• 5.4. Software

6. Antibody Production Market Assessment-by Antibody Type

• 6.1. Overview
• 6.2. Monoclonal Antibodies
• 6.3. Polyclonal Antibodies
• 6.4. Recombinant Antibodies

7. Antibody Production Market Assessment-by Source

• 7.1. Overview
• 7.2. Mice
• 7.3. Rabbit
• 7.4. Other Sources

8. Antibody Production Market Assessment-by Process

• 8.1. Overview
• 8.2. Downstream
• 8.3. Upstream

9. Antibody Production Market Assessment-by End User

• 9.1. Overview
• 9.2. Pharmaceutical & Biotechnology Companies
• 9.3. CROs & CDMOs
• 9.4. Academic & Research Institutes

10. Antibody Production Market Assessment-by Geography

• 10.1. Overview
• 10.2. North America
  • 10.2.1. U.S.
  • 10.2.2. Canada
• 10.3. Europe
  • 10.3.1. Germany
  • 10.3.2. France
  • 10.3.3. U.K.
  • 10.3.4. Italy
  • 10.3.5. Spain
  • 10.3.6. Rest of Europe
• 10.4. Asia-Pacific
  • 10.4.1. China
  • 10.4.2. India
  • 10.4.3. Japan
  • 10.4.4. Rest of Asia-Pacific
• 10.5. Latin America
  • 10.5.1. Brazil
  • 10.5.2. Mexico
  • 10.5.3. Rest of Latin America
• 10.6. Middle East & Africa

11. Competition Analysis

• 11.1. Overview
• 11.2. Key Growth Strategies
• 11.3. Competitive Benchmarking
• 11.4. Competitive Dashboard
  • 11.4.1. Industry Leaders
  • 11.4.2. Market Differentiators
  • 11.4.3. Vanguards
  • 11.4.4. Emerging Companies
• 11.5. Market Share Analysis/Market Ranking, by Key Players (2022)

12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)

• 12.1. Thermo Fisher Scientific, Inc.
• 12.2. Merck KgaA
• 12.3. Eppendorf SE
• 12.4. Agilent Technologies, Inc.
• 12.5. Sartorius AG
• 12.6. Danaher Corporation
• 12.7. Waters Corporation
• 12.8. Shimadzu Corporation
• 12.9. Solaris Biotechnology Srl
• 12.10. Infors AG

(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

13. Appendix

• 13.1. Available Customization
• 13.2. Related Reports